22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- Senior CPC official visits prominent experts
- Probe reveals woman flashed husband's credentials to bully motorist
- Storms claim five lives in Guangdong
- Dragon boat race sets stage for two months of cultural celebrations in Hainan
- 5 dead after being swept away in wild area of South China's Guangdong
- Yunnan's Gongshan plum yews: from adversity to thriving
